Welcome back to the BBAE Blog, your trusted source for the latest investment insights and analyses from the BBAE team. This week, we’re excited to share some highlights that will keep you informed and ahead of the market. Don’t forget, some of our most valuable insights are available exclusively in the BBAE Pro app—download it now to unlock full access!
- Ethos Technologies ($LIFE) IPO: Everything You Need to Know
- Delta Air Lines ($DAL) Insider Sales After January Peak
- Trending Tickers: $TLN Gas Expansion, $CRVS Trial Results, $AVAV Stop-Work Order
Need a reminder of why BBAE? We have one goal: to provide you with exclusive content and data to help you make informed investing decisions. Explore a wealth of market insights and potential investing opportunities that you can’t find anywhere else.
Ethos Technologies ($LIFE) IPO: Everything You Need to Know
Ethos Technologies Inc. is preparing to go public under the ticker $LIFE, with an IPO that highlights the rapid growth of its digital life insurance platform. In this article, we review Ethos’s S-1 filing, breaking down how its three-sided model connects consumers, insurance agents, and carriers, how the company generates revenue through commissions, and how it has scaled policy volumes while improving profitability. We also examine key financial trends, margin expansion, partner concentration, and structural considerations investors should be aware of ahead of the offering. Click here to read full article.
Delta Air Lines ($DAL) Insider Sales After January Peak
Ed Bastian, CEO at Delta Air Lines, Inc. ($DAL), sold 173,230 shares at an average price of $71.00, for a total value of about $12.30 million, reducing his disclosed stake by 21.49% in what ranks as his largest sale on record out of 62. The transaction comes as Delta shares reached an all-time high in January 2026, following a strong run supported by resilient travel demand, improved pricing power, and continued focus on premium and international routes. Insider activity has also picked up, with six insiders recording six total sales over the past 30 days, leaving investors to consider whether this round of selling signals that the rally may be nearing a pause or if it simply reflects profit taking after the stock’s move to record levels. You can track insider activity like this daily with InsiderEdge, available in the BBAE app.
Trending Tickers: $TLN Gas Expansion, $CRVS Trial Results, $AVAV Stop-Work Order
This week, several stocks attracted attention due to major developments. Here’s a breakdown:
- Talen Energy ($TLN): Talen agreed to buy three natural gas power plants in Ohio and Indiana, adding about 2.6 GW of capacity and expanding its footprint in the PJM power market. According to the company, the $3.45B deal should support long-term cash flow, though the stock gave back initial gains after an early jump.
- Corvus Pharmaceuticals ($CRVS): Corvus surged after early trial data showed its eczema drug, soquelitinib, delivered strong skin-clearing results with a clean safety profile. The company said 75% of patients hit a key improvement target after eight weeks, supporting plans to move into Phase 2 trials in 2026.
- AeroVironment ($AVAV): AeroVironment fell after the U.S. government issued a stop-work order on part of its SCAR satellite communications program. According to the company, the pause is meant to renegotiate contract terms and does not cancel the program, but it adds near-term uncertainty.
Read the full Weekly Highlights article here.
This article is for informational purposes only and is neither investment advice nor a solicitation to buy or sell securities. All investment involves inherent risks, including the total loss of principal, and past performance is not a guarantee of future results. Always conduct thorough research or consult with a financial expert before making any investment decisions. BBAE has no position in any investment mentioned.
